WILSON SONSINI

Elevar Therapeutics Completes Merger Transaction with South Korean Company HLB

CLIENT HIGHLIGHTS

December 31, 2019

On November 27, 2019, Elevar Therapeutics completed its merger transaction with HLB, a South Korean company whose shares are publicly traded on the Korean stock exchange, pursuant to which Elevar became a wholly-owned subsidiary of HLB. Elevar is a pharmaceutical company based primarily in Utah specializing in clinical development of promising therapies for unmet medical needs in cancer. Wilson Sonsini acts as patent, corporate and technology transactions counsel for Elevar, including in connection with the merger transaction.

The Wilson Sonsini team representing Elevar in the transaction includes the following attorneys:

Corporate
Jason Skolnik
Tanner Konold
Tim Conroy

Patent
Peter Kang

Tax
Jonathan Zhu
Derek Wallace

Technology Transactions
Ian Edvalson

Employment Benefits & Compensation
Brandon Gantus
Mark Cornillez-Ty